Cargando…
Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study
BACKGROUND: Reduced survival of red blood cells (RBCs) in patients with chronic kidney disease (CKD) is thought to contribute to renal anaemia. Although renal anaemia improved greatly because of the wide use of erythropoiesis-stimulating agents (ESAs) and the advancement of dialysis techniques, RBC...
Autores principales: | Zhao, Bing, Yang, Xiaowei, Li, Weidan, Zhu, Huizi, Meng, Qian, Ma, Yongjian, Liu, Yun, Zhou, Yan, Lin, Jiangong, Zhai, Chunjuan, Zhao, Lian, Sun, Jing, Wang, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469108/ https://www.ncbi.nlm.nih.gov/pubmed/37664567 http://dx.doi.org/10.1093/ckj/sfad080 |
Ejemplares similares
-
Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin
por: Yang, Xiaowei, et al.
Publicado: (2021) -
Tuberculosis in haemodialysis patients: A single centre experience
por: Rao, T. Manmadha, et al.
Publicado: (2013) -
Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy
por: Zhu, Huizi, et al.
Publicado: (2022) -
Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022) -
Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia
por: Xu, Bojun, et al.
Publicado: (2021)